Free Trial
NYSE:ENOV

Enovis (ENOV) Stock Price, News & Analysis

Enovis logo
$35.94 +0.38 (+1.07%)
Closing price 03:59 PM Eastern
Extended Trading
$35.94 0.00 (-0.01%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enovis Stock (NYSE:ENOV)

Key Stats

Today's Range
$35.21
$36.82
50-Day Range
$29.62
$37.43
52-Week Range
$28.83
$49.83
Volume
1.22 million shs
Average Volume
1.14 million shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.60
Consensus Rating
Moderate Buy

Company Overview

Enovis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

ENOV MarketRank™: 

Enovis scored higher than 72% of companies evaluated by MarketBeat, and ranked 284th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Enovis has only been the subject of 4 research reports in the past 90 days.

  • Read more about Enovis' stock forecast and price target.
  • Earnings Growth

    Earnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enovis is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enovis is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enovis has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Enovis' valuation and earnings.
  • Percentage of Shares Shorted

    10.98% of the float of Enovis has been sold short.
  • Short Interest Ratio / Days to Cover

    Enovis has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Enovis has recently decreased by 5.39%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enovis does not currently pay a dividend.

  • Dividend Growth

    Enovis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.98% of the float of Enovis has been sold short.
  • Short Interest Ratio / Days to Cover

    Enovis has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Enovis has recently decreased by 5.39%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Enovis has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Enovis this week, compared to 6 articles on an average week.
  • Search Interest

    1 people have searched for ENOV on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enovis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Enovis is held by insiders.

  • Percentage Held by Institutions

    98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enovis' insider trading history.
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

ENOV Stock Analysis - Frequently Asked Questions

Enovis' stock was trading at $43.88 at the beginning of the year. Since then, ENOV stock has decreased by 17.9% and is now trading at $36.03.

Enovis Corporation (NYSE:ENOV) issued its quarterly earnings data on Thursday, May, 8th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. The company's revenue was up 8.2% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional shareholders of Enovis include Confluence Investment Management LLC (0.12%), Central Valley Advisors LLC (0.10%) and Fiduciary Financial Group LLC (0.02%). Insiders that own company stock include Matthew L Trerotola, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Phillip Benjamin (Ben) Berry, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner.
View institutional ownership trends
.

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
5/08/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Medical Equipment
Current Symbol
NYSE:ENOV
CIK
1420800
Employees
7,367
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$46.00
Potential Upside/Downside
+56.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
12.72
P/E Growth
N/A
Net Income
-$825.49 million
Pretax Margin
-37.25%

Debt

Sales & Book Value

Annual Sales
$2.11 billion
Cash Flow
$19.61 per share
Price / Cash Flow
1.81
Book Value
$45.10 per share
Price / Book
0.79

Miscellaneous

Free Float
55,581,000
Market Cap
$2.03 billion
Optionable
Optionable
Beta
1.70
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSE:ENOV) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners